792 related articles for article (PubMed ID: 28838659)
21. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent.
Nandi PK; Nicole JC
J Mol Biol; 2004 Nov; 344(3):827-37. PubMed ID: 15533448
[TBL] [Abstract][Full Text] [Related]
22. The structure of prion: is it enough for interpreting the diverse phenotypes of prion diseases?
Tian C; Dong X
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):429-34. PubMed ID: 23459557
[TBL] [Abstract][Full Text] [Related]
23. [Prions and their biology].
Gasset M; Westaway D
Rev Neurol; 2000 Jul 16-31; 31(2):129-32. PubMed ID: 10951668
[TBL] [Abstract][Full Text] [Related]
24. Prion protein interconversions and the transmissible spongiform encephalopathies.
Horiuchi M; Caughey B
Structure; 1999 Oct; 7(10):R231-40. PubMed ID: 10545332
[TBL] [Abstract][Full Text] [Related]
25. Prion protein misfolding and disease.
Moore RA; Taubner LM; Priola SA
Curr Opin Struct Biol; 2009 Feb; 19(1):14-22. PubMed ID: 19157856
[TBL] [Abstract][Full Text] [Related]
26. Prion protein oligomer and its neurotoxicity.
Huang P; Lian F; Wen Y; Guo C; Lin D
Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):442-51. PubMed ID: 23557632
[TBL] [Abstract][Full Text] [Related]
27. Prion protein and its conformational conversion: a structural perspective.
Surewicz WK; Apostol MI
Top Curr Chem; 2011; 305():135-67. PubMed ID: 21630136
[TBL] [Abstract][Full Text] [Related]
28. Experimental approaches to TSE prevention via inhibition of prion formation.
Politopoulou G
Protein Pept Lett; 2004 Jun; 11(3):249-55. PubMed ID: 15182226
[TBL] [Abstract][Full Text] [Related]
29. A new mechanism for transmissible prion diseases.
Makarava N; Kovacs GG; Savtchenko R; Alexeeva I; Ostapchenko VG; Budka H; Rohwer RG; Baskakov IV
J Neurosci; 2012 May; 32(21):7345-55. PubMed ID: 22623680
[TBL] [Abstract][Full Text] [Related]
30. Kinetic intermediate in the folding of human prion protein.
Apetri AC; Surewicz WK
J Biol Chem; 2002 Nov; 277(47):44589-92. PubMed ID: 12356762
[TBL] [Abstract][Full Text] [Related]
31. Transmission and Replication of Prions.
Marín-Moreno A; Fernández-Borges N; Espinosa JC; Andréoletti O; Torres JM
Prog Mol Biol Transl Sci; 2017; 150():181-201. PubMed ID: 28838661
[TBL] [Abstract][Full Text] [Related]
32. De novo generation of infectious prions in vitro produces a new disease phenotype.
Barria MA; Mukherjee A; Gonzalez-Romero D; Morales R; Soto C
PLoS Pathog; 2009 May; 5(5):e1000421. PubMed ID: 19436715
[TBL] [Abstract][Full Text] [Related]
33. Role of prion protein aggregation in neurotoxicity.
Corsaro A; Thellung S; Villa V; Nizzari M; Florio T
Int J Mol Sci; 2012; 13(7):8648-8669. PubMed ID: 22942726
[TBL] [Abstract][Full Text] [Related]
34. Infectivity-associated PrP(Sc) and disease duration-associated PrP(Sc) of mouse BSE prions.
Miyazawa K; Okada H; Masujin K; Iwamaru Y; Yokoyama T
Prion; 2015; 9(5):394-403. PubMed ID: 26555211
[TBL] [Abstract][Full Text] [Related]
35. Involvement of trace elements in the pathogenesis of prion diseases.
Mizuno D; Koyama H; Ohkawara S; Sadakane Y; Kawahara M
Curr Pharm Biotechnol; 2014; 15(11):1049-57. PubMed ID: 25373386
[TBL] [Abstract][Full Text] [Related]
36. The role of rafts in the fibrillization and aggregation of prions.
Pinheiro TJ
Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
[TBL] [Abstract][Full Text] [Related]
37. Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.
Caughey B; Baron GS; Chesebro B; Jeffrey M
Annu Rev Biochem; 2009; 78():177-204. PubMed ID: 19231987
[TBL] [Abstract][Full Text] [Related]
38. In Vitro Prion Amplification Methodology for Inhibitor Screening.
Vieira TCRG; Silva JL
Methods Mol Biol; 2019; 1873():305-316. PubMed ID: 30341619
[TBL] [Abstract][Full Text] [Related]
39. Prions: a model of conformational disease?
Morinet F
Pathol Biol (Paris); 2014 Apr; 62(2):96-9. PubMed ID: 24656441
[TBL] [Abstract][Full Text] [Related]
40. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
